United Therapeutics shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $400 to $572.
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics shares rise as Oppenheimer maintains an Outperform rating and raises the price target from $400 to $572.
August 28, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics shares are trading higher following Oppenheimer's decision to maintain an Outperform rating and increase the price target from $400 to $572.
The increase in price target from $400 to $572 by Oppenheimer, along with the maintained Outperform rating, is a strong positive signal for investors, likely leading to increased buying interest and a rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100